1. United States Stocks

  2. •

    Health services

  3. •

    Services to the health industry
Psychemedics Corp.

Psychemedics Corp.

OOTC:PMDI
2.49
USD
+0.29
(+13.18%)
-0.32EPS
13.69MMarket Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
4.8
5.07
5.45
4.99
7.14
7.23
7.75
6.83
3.86
4.46
4.44
3.85
3.22
3.33
Basic EPS, GAAP
0.57
0.72
0.6
0.28
1.22
1.11
0.83
0.28
-0.7
-0.12
-0.19
-0.72
-0.3
-0.32
Free Cash Flow per Basic Share
0.17
0.83
-0.58
0.52
1.33
1.45
1.22
0.48
-0.92
0.04
0.83
-0.29
0.14
0.14
Dividend per Share
0.6
0.6
0.6
0.6
0.6
0.6
0.69
0.72
0.18
0.05
0.21
0.14
- -
- -
Book Value per Share
2.13
2.31
2.39
2.15
2.86
3.39
3.4
3.05
2.26
2.19
1.9
1.15
0.84
0.84
Tangible Book Value per Share
2.13
2.31
2.39
2.15
2.86
3.39
3.4
3.05
2.26
2.19
1.9
1.15
0.84
0.84
Basic Weighted Avg Shares
5
5
5
5
5
5
6
6
6
6
6
6
6
6
Sales/Revenue/Turnover
25
27
29
27
39
40
43
38
21
25
25
22
20
20
Operating Margin (%)
19.57
21.24
16.06
5.45
25.94
20.55
17.83
7.96
-28.4
0.84
-4.29
-13.22
-9.62
-9.62
Depreciation Expense
1
1
1
2
2
3
3
3
4
4
3
3
2
2
Net Income, GAAP
3
4
3
2
7
6
5
2
-4
-1
-1
-4
-2
-2
Effective Tax Rate (%)
39.65
34.38
30.8
- -
33.06
25.14
40.1
49.54
- -
- -
- -
- -
- -
- -
Profit Margin (%)
11.81
14.16
10.98
5.6
17.13
15.42
10.74
4.09
-18.07
-2.67
-4.29
-18.8
-9.45
-9.45
Working Capital
7
7
7
5
6
10
10
7
6
4
4
2
2
2
LT Debt
- -
- -
5
4
2
2
1
4
7
3
2
1
- -
- -
Total Equity
11
12
13
12
16
19
19
17
13
12
11
7
5
5
Return on Invested Capital (%)
27.12
32.24
20.86
- -
36.83
28.91
20.75
6.84
- -
- -
- -
- -
- -
- -
Return on Capital (%)
26.77
32.39
20.45
- -
37.03
30.13
21.94
7.15
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
26.77
32.39
25.53
12.33
48.96
35.77
24.54
8.67
-26.31
-5.37
-9.42
-47.63
-31.54
-31.54

Capital Structure

USD

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
6
6
Market Capitalization
14
14
14

Working Capital

USD

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
6
6
5
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
3
3
3
Inventories
- -
- -
- -
Total Current Liabilities
4
4
3
Payables & Accruals
3
3
2
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.66%
-20.19%
-23.11%
Free Cash Flow
114.26%
248.71%
-151.44%
Net Income, GAAP
4.73%
-28.4%
-55.2%
Sales/Revenue/Turnover
-1.42%
-9.75%
-10.92%
Total Cash Common Dividend
6.79%
9.11%
-100%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
7
7
7
6
25
2023
6
6
6
5
22
2024
5
5
5
4
20

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
0.01
-0.06
-0.02
-0.12
-0.19
2023
-0.07
-0.13
-0.36
-0.16
-0.72
2024
-0.12
-0.14
-0.09
0.03
-0.3

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
0.07
0.07
0.21
2023
- -
- -
- -
- -
0.14
2024
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Brian Hullinger
Sector
Health services
Industry
Services to the health industry
Address
Dallas United States
IPO Date
Jan 22, 1987
Website
psychemedics.com
Similar Companies
Quest Diagnostics Incorporated (NYSE:DGX)
Pro Medicus, Ltd. (ASX:PME)
Astrana Health Inc. (NASDAQ:ASTH)
NRC Health (NASDAQ:NRC)
teno.Holdings Co., Ltd. (TSE:7037)
Tameny, Inc. (TSE:6181)
Business
Psychemedics Corporation is a diagnostic services company specializing in the development and delivery of non-invasive hair-based drug and alcohol testing services. Founded in 1986 and headquartered in Acton, Massachusetts, the company maintains its primary College of American Pathologists (CAP) accredited and CLIA-certified laboratory testing facility in Culver City, California, serving corporate employers, government and law enforcement entities, financial institutions, educational organizations, and retail consumers across the United States and international markets, including Brazil. Psychemedics Corporation provides toxicological testing solutions based on a patented digestion method that extracts entrapped drug molecules from hair keratin for immunoassay screening and mass spectrometry confirmation (LC/MS/MS and GC/MS/MS). The company's core offerings include standard 5-panel hair drug assays detecting cocaine, marijuana, phencyclidine (PCP), amphetamines, and opiates; expanded multi-drug testing panels covering fentanyl, synthetic opioids, nitazenes, benzodiazepines, and prescription stimulants; Ethyl Glucuronide (EtG) hair testing for monitoring approximately 90-day alcohol consumption patterns; PDT-90 patented home-collection drug testing kits designed for consumer and parental use; customized sample collection kits; specialized workforce analytics tools including Quartile Reporting; and forensic expert consultation and legal testimony services. In recent corporate developments, Psychemedics completed a strategic capital restructuring in December 2024, voluntarily delisting its common stock from the Nasdaq Capital Market and deregistering under the Securities Exchange Act of 1934 to transition its shares to the OTC Markets under the ticker PMDI, a transaction executed alongside a reverse-forward stock split and a major equity financing agreement with 3K Limited Partnership and director Peter Kamin. The company has also expanded its risk-intelligence and data solutions by rolling out enhanced analytics platforms and publishing dedicated workforce and transportation drug monitoring reports tracking synthetic drug and multi-substance abuse trends.